The company was founded by Professor John Campbell, a renowned T cell therapy manufacturing expert and immunologist, and Delin Ventures, a specialist life sciences investor.

Swarm's Swarm-T platform leverages immune system priming with proprietary ex vivo cell processing to generate unprecedented, large numbers of T cells with desired phenotypes to home, infiltrate and kill cancer cells. Swarm Oncology expects to advance its first therapeutic candidate into clinical trials sometime in 2025/26.